Compounded vs Name-Brand Medication Advertising Rules

Compounded and brand-name medication advertising rules are different in ways that matter significantly for telehealth brands. The differences are not cosmetic — they reflect fundamentally different legal frameworks for how FDA-approved and non-FDA-approved drugs can be promoted to consumers. If your telehealth platform offers both compounded GLP-1 medications and brand-name Ozempic or Wegovy prescriptions, you are operating under two distinct advertising frameworks simultaneously, and mixing up the rules for one with the other creates compliance exposure on both sides.

This guide explains the structural differences between the two frameworks, the specific claim types that are allowed for each, and the practical implications for a telehealth brand building an advertising program that covers both compounded and branded medication access.

The FDA's Different Treatment of Branded and Compounded Drug Advertising

For FDA-approved prescription drugs like Ozempic and Wegovy, the FDA's Office of Prescription Drug Promotion (OPDP) has regulatory authority over direct-to-consumer advertising. Branded drug advertising must not be false or misleading, must present a fair balance of information about risks and benefits, and must include required risk information (the "major statement" in broadcast media, the "brief summary" in print). Branded drug ads can make the specific claims supported by the drug's FDA-approved labeling — those claims have been reviewed by FDA as part of the approval process.

For compounded medications, OPDP's authority is more limited, but the FDA's broader misbranding and mislabeling authority under 21 U.S.C. § 352 applies. A compounded medication that is advertised with false or misleading claims is misbranded. The key difference: compounded medications do not have FDA-approved labeling, so there is no approved claim set that the advertiser can point to as their reference for what is allowed. Every efficacy or safety claim made for a compounded product must be substantiated independently — the advertiser cannot borrow substantiation from the branded drug's approval.

Substantiation Requirements Compared

For branded drugs, the FDA-approved prescribing information provides the substantiation foundation for advertising claims. A telehealth brand that says Wegovy is "FDA-approved for chronic weight management in adults with obesity" is making a claim that is directly supported by Wegovy's approved labeling. The claim requires no additional substantiation — it is factually accurate based on FDA's approval. For compounded semaglutide, no equivalent approval exists. A telehealth brand advertising compounded semaglutide as effective for chronic weight management is making an efficacy claim that must be independently substantiated through competent and reliable scientific evidence.

This substantiation gap is significant in practice. Most compounded GLP-1 telehealth brands do not have independent clinical trial data on their specific compounded product. They rely on the clinical data from the branded drugs — but that data substantiates claims about the branded drug, not the compounded version. The FDA has taken the position that compounded products are distinct from the reference listed drug, and that clinical data for the branded drug cannot be freely used to substantiate claims about the compounded version. This is a core reason why the FDA targeted equivalence claims in its September 2025 warning letter wave. See our full analysis of why equivalence claims for compounded GLP-1 are prohibited.

Pricing and Access Claim Differences

One area where compounded GLP-1 telehealth advertising has a genuine advantage over branded drug advertising is pricing claims. Telehealth brands commonly advertise the cost difference between compounded semaglutide and brand-name Ozempic or Wegovy as a key value proposition. Making accurate pricing comparisons — "compounded semaglutide available from as little as [X] per month, compared to [Y] or more for brand-name Ozempic without insurance" — is generally permissible as long as the price comparison is accurate and does not imply that the products are therapeutically equivalent.

Branded drug pricing advertising is constrained by the manufacturer's policies and trademark terms of use in addition to FDA and FTC rules. Novo Nordisk and Eli Lilly can restrict how third parties use their brand names in advertising, including restricting comparative pricing claims that use their trademarks. This means a compounded GLP-1 telehealth brand making comparative pricing claims that include brand names should review the trademark policies of those brands alongside the FDA and FTC requirements.

FDA Approval Status Disclosure Requirements

Compounded medication advertising must clearly communicate that the product is compounded — meaning it is not FDA-approved — in any context where a consumer might otherwise believe they are receiving an FDA-approved product. This disclosure is required not just in advertising but in all patient-facing materials, including the patient intake process, prescriptions, and medication packaging. The FDA's position is that patients have a right to know when they are receiving a non-FDA-approved compounded product rather than an FDA-approved drug.

For telehealth brands offering both compounded and branded options, this disclosure requirement creates a design challenge for advertising. If your ad promotes "access to semaglutide" without specifying whether the product is compounded or branded, a consumer might reasonably assume they are getting the FDA-approved version. Advertising that covers both options should clearly differentiate them — or choose to advertise only one option in a given campaign to avoid the ambiguity.

How Platform Policies Apply Differently to Each Category

Meta and Google treat branded drug advertising and compounded medication advertising differently at the platform policy level. For branded drugs, platforms' existing pharmaceutical advertising certification pathways — requiring LegitScript for online pharmacies and the Google Healthcare and Medicines certification — apply in a relatively well-defined way. For compounded medications, the platform policies are less specific, which means more variability in review outcomes.

The practical effect is that branded drug telehealth advertising on Meta and Google, while requiring certification, has a clearer compliance pathway than compounded medication advertising. Once a telehealth brand obtains LegitScript certification and meets the platform's requirements, it can run branded drug-adjacent advertising with a degree of predictability. Compounded medication advertising faces more ambiguity in the review process because the platforms have not developed the same specific policies for non-FDA-approved compounded products. This ambiguity translates to higher rejection rates and more variability in what passes review, even for nominally similar creative. See the full overview of FDA GLP-1 warning letters for the enforcement context that shapes platform policy development in this area.

Building an Advertising Strategy That Covers Both Options

Telehealth brands that offer both compounded and branded medication access need advertising strategies that clearly segment the two. The simplest approach is to run service-level advertising that does not specify whether the medication prescribed will be compounded or branded — "connect with a licensed provider for prescription weight loss treatment" — and let the clinical consultation determine which option is appropriate for each patient. This approach covers the full patient population without requiring the advertising to navigate the compounded-vs-branded regulatory distinction.

When product-specific advertising is desired — because compounded pricing or branded FDA approval status is a specific competitive advantage you want to highlight — run separate campaigns for each, each using claim language appropriate to that specific product's regulatory status. Do not mix claim types across products in the same ad or landing page, as this creates the blurring of the regulatory distinction that both FDA and platform policies are designed to prevent. See our comprehensive FDA advertising rules guide for the full framework.